DCM
AVTX icon

DAFNA Capital Management’s Avalo Therapeutics AVTX Stock Holding History

DAFNA Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-110
Closed -$827K – 82
2020
Q2 		$827K Buy
+110
New +$799K 0.24% 62

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DAFNA Capital Management's AVTX Position: Q3 2020 in Review

DAFNA Capital Management sold out of Avalo Therapeutics (AVTX) in Q3 2020, closing a stake of 110 shares — an estimated $827K sold.

DAFNA Capital Management first reported a position in AVTX in Q2 2020 and held it in 1 quarter. The position peaked at $827K in Q2 2020. 52 funds tracked by Wall St. Rank hold AVTX as of Q3 2020.

  • DAFNA Capital Management reported no remaining Avalo Therapeutics position as of Q3 2020 after selling out during the quarter.
  • DAFNA Capital Management sold 110 Avalo Therapeutics shares in Q3 2020, an estimated $827K.
  • DAFNA Capital Management first reported a position in Avalo Therapeutics in Q2 2020 and held it in 1 quarter.
  • DAFNA Capital Management's Avalo Therapeutics position peaked at $827K in Q2 2020.
  • 52 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2020.

Based on DAFNA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.